Examination of Fiscal Management and the Allocation of Care Act Resources US Department of Health and Human Services: Health REsources and Services Administration
INTRODUCTION
HIV/HCV Coinfection
HCV Treatment
Response to HCV Treatment: Prognostic Factors
Liver Biopsy
Treatment Strategies
Side Effects and Strategies for Managing Them
The Week 12 Early-Stopping Rule
Treating HCV: Long-Term Benefits
Treatment of Acute HCV
Expanding Access to Treatment
Barriers and Key Issues
Conclusion
Resources
References

Treating HCV: Long-Term Benefits

In HCV monoinfection, follow-up studies of people who experience SVR have found that more than 85 percent maintain undetectable HCV RNA levels for up to 10 years after completion of HCV treatment130-132; retrospective studies have reported a reduction in liver-related deaths, especially among people who have SVR.133,134 Data on long-term outcomes of coinfected patients are limited; one study reported that no HCV-related clinical complications occurred among sustained virological responders after a mean posttreatment follow-up period of 58 months.135

Treatment of HCV offers significant benefits to people with coinfection, even in the absence of SVR. HCV treatment may improve the condition of the liver, even in virologic nonresponders.88,136 Moreover—and crucially—HCV treatment may increase tolerability of antiretroviral therapy for HIV/AIDS.137

 
 
<< The Week 12 Early-Stopping Rule • Treatment of Acute HCV >>